GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » The Cooper Companies Inc (STU:CP60) » Definitions » EBIT

The Cooper (STU:CP60) EBIT : €543 Mil (TTM As of Apr. 2024)


View and export this data going back to 1983. Start your Free Trial

What is The Cooper EBIT?

The Cooper's earnings before interest and taxes (EBIT) for the three months ended in Apr. 2024 was €148 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Apr. 2024 was €543 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. The Cooper's annualized ROC % for the quarter that ended in Apr. 2024 was 3.81%. The Cooper's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2024 was 25.78%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. The Cooper's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Apr. 2024 was 2.75%.


The Cooper EBIT Historical Data

The historical data trend for The Cooper's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Cooper EBIT Chart

The Cooper Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 493.04 257.81 443.59 540.59 490.74

The Cooper Quarterly Data
Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 83.63 131.62 125.67 137.61 148.10

Competitive Comparison of The Cooper's EBIT

For the Medical Instruments & Supplies subindustry, The Cooper's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Cooper's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where The Cooper's EV-to-EBIT falls into.



The Cooper EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Apr. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €543 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


The Cooper  (STU:CP60) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

The Cooper's annualized ROC % for the quarter that ended in Apr. 2024 is calculated as:

ROC % (Q: Apr. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jan. 2024 ) + Invested Capital (Q: Apr. 2024 ))/ count )
=602.816 * ( 1 - 31.62% )/( (10736.102 + 10908.408)/ 2 )
=412.2055808/10822.255
=3.81 %

where

Invested Capital(Q: Jan. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11045.927 - 185.711 - ( 124.114 - max(0, 885.778 - 1646.8+124.114))
=10736.102

Invested Capital(Q: Apr. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11228.177 - 215.012 - ( 104.757 - max(0, 887.73 - 1732.588+104.757))
=10908.408

Note: The Operating Income data used here is four times the quarterly (Apr. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

The Cooper's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Apr. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jan. 2024  Q: Apr. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=592.38/( ( (1544.26 + max(679.228, 0)) + (1593.068 + max(778.965, 0)) )/ 2 )
=592.38/( ( 2223.488 + 2372.033 )/ 2 )
=592.38/2297.7605
=25.78 %

where Working Capital is:

Working Capital(Q: Jan. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(597.618 + 686.205 + 238.863) - (185.711 + 112.363 + 545.384)
=679.228

Working Capital(Q: Apr. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(641.868 + 722.673 + 263.29) - (215.012 + 113.424 + 520.43)
=778.965

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Apr. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

The Cooper's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Apr. 2024 )
=542.992/19775.562
=2.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


The Cooper EBIT Related Terms

Thank you for viewing the detailed overview of The Cooper's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


The Cooper (STU:CP60) Business Description

Traded in Other Exchanges
Address
6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, USA, 94583
The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the U.S., and controls 17% of the U.S. IUD market.

The Cooper (STU:CP60) Headlines

No Headlines